Public Health
The public-health architecture in PA-3 — disease control, vaccination, FQHCs, environmental health, harm reduction — and what 2025–2026 changed.
Federal public health institutions are simultaneously being restructured through executive action and constrained by federal courts. The Murphy preliminary injunction (March 16, 2026) restored the pre-2026 childhood vaccine schedule. The Braidwood resolution (June 27, 2025) preserved ACA preventive-services coverage. State and local layers in Pennsylvania are selectively diverging where federal architecture is rolling back. The Federally Qualified Health Centers that many PA-3 households rely on for primary care, behavioral health, and harm reduction are now operating on appropriation cycles measured in months, not years.
The shape of the system
The federal public health architecture is a stack: HHS, CDC, FDA at the federal level; Pennsylvania DOH operating under the Disease Prevention and Control Law of 1955; the Philadelphia Department of Public Health under Title 6 of the Philadelphia Code and the Home Rule Charter. Through 2025–2026, that stack has been under simultaneous restructuring and judicial constraint. Approximately 18% of the FDA workforce has been reduced through formal RIF; HHS aggregate workforce reduction (including voluntary separations) is closer to 25%. The Prevention and Public Health Fund has been rescinded for cumulative roughly $11.85 billion across FY2013–FY2027, with FY2026 elimination proposed. The Murphy injunction and the Rhode Island injunction operate as court-imposed checks on the most aggressive elements of restructuring.
Inside this restructuring, substantive bright spots: the Braidwood resolution preserved the ACA § 2713 preventive-services mandate nationwide. The Inflation Reduction Act's Medicare Drug Price Negotiation Program continues, with Round 1 prices effective January 1, 2026 and Round 2 finalized for January 1, 2027. The DEA Schedule III rescheduling for state-licensed medical cannabis opened a § 280E relief pathway in April 2026. Pennsylvania's Overdose Prevention Program distributed approximately 800,000 naloxone doses and 737,000 test strips in 2025, with documented overdose-reversal counts around 9,500. Philadelphia's overdose mortality declined sharply: from 1,376 deaths in 2022 to 1,045 in 2024 to 747 preliminary in 2025. Pennsylvania statewide fell from 3,340 in 2024 to 2,178 preliminary in 2025 — a 29% year-over-year decline.
The structural pressure point for PA-3 is the safety-net medical infrastructure most heavily relied on by lower-income residents. Federally Qualified Health Centers — Philadelphia FIGHT, Puentes de Salud, MANNA, Resources for Human Development, Family Practice and Counseling Network — operate on § 330 mandatory funding extended only through December 2026 under the 2026 Consolidated Appropriations Act. No multi-year reauthorization passed despite sustained advocacy. The OBBBA Medicaid changes (6-month redetermination, work-reporting requirements, provider-tax safe-harbor stepdown) threaten FQHC financial stability across the next several years because Medicaid revenue is roughly 40%+ of the average FQHC revenue base. Temple Health is operating at structural pressure but stable in the near term — FY25 $22M operating profit, BBB rating maintained, Q1 FY26 $15M loss but improving. The same PA-3 households who use Temple and the FQHC network are the ones whose Medicaid coverage the OBBBA changes are most likely to interrupt.